glp 1 drugs for inflammation Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent 8 Benefits of GLP‑1's Beyond
Description
2020;130 doi: 10.1016/j.biopha.2020.110523
& Shannon, R
Long-acting, subcutaneously administered, PYY RA are undergoing early phase clinical trials as obesity treatments either alone or in combination with GLP-1 RA (Table 1, NCT02568306 and NCT03574584)
Diabetes Care 37 , 21412148 (2014)
[DOI] [PMC free article] [PubMed] [Google Scholar] 56
